Clinical trial
EMMA-1 (Erbitux for Multiple Myeloma)
NCT00368121 · Prof. Dr. Andreas Engert, Other · Terminated
Key facts
| NCT number | NCT00368121 |
|---|---|
| Title | EMMA-1 (Erbitux for Multiple Myeloma) |
| Official title | Phase II Study of Cetuximab for the Refractory or Relapsed Multiple Myeloma EMMA-1(Erbitux for Multiple Myeloma) |
| Acronym | EMMA-1 |
| Lead sponsor | Prof. Dr. Andreas Engert, Other |
| Collaborators | The Clinical Trials Centre Cologne |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Cetuximab +/- Dexamethasone |
| Enrollment | 13 |
| Start date | Aug 1, 2006 |
| Primary completion | Jun 1, 2012 |
| Completion | Jun 1, 2012 |
| First posted | Aug 24, 2006 |
| Last update posted | Jul 13, 2012 |
| Countries | Germany |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: